Heartflow (NasdaqGS:HTFL) 2026 Conference Transcript

HeartFlow Conference Call Summary Company Overview - Company: HeartFlow (NasdaqGS:HTFL) - Industry: Healthcare Technology, specifically focused on AI applications for diagnosing coronary artery disease [2][3] Core Business and Market Position - HeartFlow utilizes AI to diagnose coronary artery disease, addressing a critical health issue as heart disease is the leading cause of death globally [2] - The company aims to establish a new standard of care with its HeartFlow technology, which is FDA cleared and reimbursed by Medicare and commercial payers [3][4] - HeartFlow's current penetration in the non-invasive testing market is approximately 2%, with a total addressable market (TAM) of about $5 billion, based on 9.5 million non-invasive tests conducted annually in the U.S. [7][8] Technology and Product Offerings - HeartFlow's technology operates on coronary CT images, providing insights through a cloud-based platform [6][15] - The platform includes: - RoadMap Analysis: A workflow tool for CT readers to enhance reading speed and accuracy [16] - Plaque Analysis: Measures plaque types with high precision, reimbursed by Medicare and commercial payers [17][46] - FFRCT Analysis: Models blood flow to assess the need for intervention [18] - PCI Navigator Tool: Aids interventional cardiologists in planning procedures [19][64] Clinical Data and Algorithm Development - HeartFlow has accumulated approximately 160 million annotated CT images, which are proprietary and form a significant competitive advantage [27][28] - The company has over 600 peer-reviewed clinical publications, supporting its technology and aiding in shifting clinical practice patterns [29][30] - The algorithm's efficiency has improved significantly, reducing the time for quality control from 20 hours to about 20 minutes [24] Market Expansion and Future Growth - HeartFlow plans to expand its offerings, including the launch of the PCI Navigator tool in 2026 and a serial Plaque Analysis in 2027 to track disease progression [64][65] - The company aims to enter the high-risk asymptomatic patient market, which represents an additional $6 billion TAM, with clinical trials planned for various subpopulations [66][67] - The focus on plaque analysis is expected to double the applicable patient population compared to FFRCT, enhancing revenue potential [50][52] Competitive Advantages and Barriers to Entry - HeartFlow's bi-directional data pipes facilitate seamless integration with healthcare systems, enhancing customer stickiness and operational efficiency [41][42] - The regulatory environment and the need for FDA clearance create barriers for new entrants, solidifying HeartFlow's market position [29][45] Conclusion - HeartFlow is positioned for significant growth with its innovative technology and expanding product offerings, addressing a critical need in coronary artery disease diagnosis and management. The company is focused on leveraging its extensive clinical data and proprietary algorithms to enhance patient care and drive future revenue growth [63][72]